

Supplementary information

Supplementary Table 1. 4120 surveys were completed in total. Surveys were received from the following countries.

Europe	Number of responses
Austria	148
Belgium	56
Czech Republic	152
Denmark	76
Finland	214
France	137
Greece	115
Gulf Cooperation Council (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates)	111
Hungary	484
Ireland	114
Israel	512
Italy	150
The Netherlands	20
Norway	62
Poland	191
Portugal	199
Slovakia	240
Slovenia	59
Spain	140
Sweden	139
Switzerland	25
Turkey	503
United Kingdom	35

Supplementary Table 2.

	Nurses (n)	Nurses (%)
Q 5. What impact do you think that improving adherence would have on the outcome of schizophrenia? (N=4120)		
Huge impact	1290	31
Sizeable impact	2233	54
Marginal impact	269	7
No impact	58	1
No answer	270	7
Q 8. In your opinion, would ensuring continuous medication with a LAI antipsychotic medication have long-term outcome benefits to patients with schizophrenia? (N=4120)		
Yes; long-term outcome benefits	3809	92
No long-term outcome benefits	144	3
No answer	167	4
Q 9. When you administer a LAI antipsychotic medication, do you have a preferred site? (N=4100; not asked in the Netherlands)		
Gluteal	2102	52
Deltoid	543	13
No preference	1209	29
No response	246	6